Aurobindo Pharma has informed that the officials of the Company will be participating in the investor meetings, as per the schedule attached. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations.
The above information is a part of company’s filings submitted to BSE.